Obesity medicines, such as semaglutide (Wegovy ®,) offer an effective treatment for obesity and cardiovascular disease, as part of a range of interventions for eligible patients, used alongside a reduced calorie diet and increased physical activity.The Scottish Government published a national consensus statement in September 2024, to support Health Boards to consider how best to implement these obesity medicines.